TickerFacts.

Moderna, Inc. (MRNA): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$1.87B
Year ended 2025-12-31
-$1.07B
Trailing 12 months to 2026-06-30
$13.62B2016-12-31: $66.73M2017-12-31: -$331.48M2018-12-31: -$330.87M2019-12-31: -$459.00M2020-12-31: $2.03B2021-12-31: $13.62B2022-12-31: $4.98B2023-12-31: -$3.12B2024-12-31: -$3.00B2025-12-31: -$1.87B-$1.87B
2016-12-31 Operating Cash Flow (USD) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-31-$1.87Bn/m2026-02-20, From 2025-01-01
2024-12-31-$3.00Bn/m2026-02-20, From 2024-01-01
2023-12-31-$3.12Bn/m2026-02-20, From 2023-01-01
2022-12-31$4.98B-63.4%2025-02-21, From 2022-01-01
2021-12-31$13.62B+571.9%2024-02-23, From 2021-01-01
2020-12-31$2.03Bn/m2023-02-24, From 2020-01-01
2019-12-31-$459.00Mn/m2022-02-25, From 2019-01-01
2018-12-31-$330.87Mn/m2021-02-26, From 2018-01-01
2017-12-31-$331.48Mn/m2020-02-27, From 2017-01-01
2016-12-31$66.73Mn/a2019-03-13, From 2016-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
Moderna, Inc. (MRNA)2025-12-31-$1.87Bn/m
Qiagen N.V. (QGEN)2025-12-31$654.33M-2.9%
Exelixis, Inc. (EXEL)2026-01-02$884.27M+26.3%
Halozyme Therapeutics, Inc. (HALO)2025-12-31$651.56M+36.0%
Neurocrine Biosciences Inc (NBIX)2025-12-31$782.70M+31.5%
Bio-Techne Corp (TECH)2026-06-30$292.07M+1.6%
Novavax Inc (NVAX)2025-12-31-$244.63Mn/m
BioCryst Pharmaceuticals Inc (BCRX)2025-12-31$347.37Mn/m
Repligen Corp (RGEN)2025-12-31$117.42M-33.1%

Compare MRNA, QGEN, EXEL, HALO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗